Literature DB >> 10861008

Chromosome instability contributes to loss of heterozygosity in mice lacking p53.

C Shao1, L Deng, O Henegariu, L Liang, P J Stambrook, J A Tischfield.   

Abstract

The p53 tumor suppressor protein participates in multiple cellular processes including cell cycle checkpoints and programmed cell death. In cell lines, loss of p53 function is associated with increased genetic instability including aneuploidy, gene amplification, and point mutation. Although similar genetic instability often accompanies the progression of malignancy in tumors, its role in tumor initiation in normal cells is not clear. To study whether or not loss of p53 leads to genetic instability in normal cells in vivo, we have examined mechanisms of loss of heterozygosity (LOH) at the Aprt (adenine phosphoribsyltransferase) and flanking loci in normal fibroblasts and T lymphocytes of p53-deficient mice. Somatic cell variants that arose in vivo as a consequence of genetic or epigenetic alterations abolishing Aprt function were selected and expanded in vitro by virtue of their resistance to 2,6-diaminopurine (DAP). We observed that p53 null mice produced about three times as many DAP-resistant fibroblast colonies than wild-type mice, but the frequency of DAP-resistant T lymphocyte colonies was not significantly changed. Mitotic recombination, but not point mutation, partly accounted for the increase in the frequency of DAP-resistant fibroblasts. Most significantly, chromosome loss/duplication and interstitial deletion, which were extremely rare events in the wild-type mice, represented a significant proportion of LOH events in both fibroblasts and T lymphocytes of p53 null mice. Also, increased interstitial deletion was observed in fibroblasts of p53 heterozygous mice. These data suggest that increased genetic variation, including chromosome instability, starts at the initiation stage of tumorigenesis when functional p53 is absent or reduced.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861008      PMCID: PMC16558          DOI: 10.1073/pnas.97.13.7405

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control.

Authors:  H Willers; E E McCarthy; B Wu; H Wunsch; W Tang; D G Taghian; F Xia; S N Powell
Journal:  Oncogene       Date:  2000-02-03       Impact factor: 9.867

2.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53.

Authors:  L R Livingstone; A White; J Sprouse; E Livanos; T Jacks; T D Tlsty
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

3.  Enhanced proliferative potential in culture of cells from p53-deficient mice.

Authors:  T Tsukada; Y Tomooka; S Takai; Y Ueda; S Nishikawa; T Yagi; T Tokunaga; N Takeda; Y Suda; S Abe
Journal:  Oncogene       Date:  1993-12       Impact factor: 9.867

4.  Mitotic recombination produces the majority of recessive fibroblast variants in heterozygous mice.

Authors:  C Shao; L Deng; O Henegariu; L Liang; N Raikwar; A Sahota; P J Stambrook; J A Tischfield
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

5.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.

Authors:  L A Donehower; M Harvey; B L Slagle; M J McArthur; C A Montgomery; J S Butel; A Bradley
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

6.  Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization.

Authors:  F Z Bischoff; S O Yim; S Pathak; G Grant; M J Siciliano; B C Giovanella; L C Strong; M A Tainsky
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

7.  Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles.

Authors:  Y Yin; M A Tainsky; F Z Bischoff; L C Strong; G M Wahl
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

8.  Tumor spectrum analysis in p53-mutant mice.

Authors:  T Jacks; L Remington; B O Williams; E M Schmitt; S Halachmi; R T Bronson; R A Weinberg
Journal:  Curr Biol       Date:  1994-01-01       Impact factor: 10.834

9.  Metabolic activation of 2,6-diaminopurine and 2,6-diaminopurine-2'-deoxyriboside to antitumor agents.

Authors:  G Weckbecker; J G Cory
Journal:  Adv Enzyme Regul       Date:  1989

10.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.

Authors:  K M Dameron; O V Volpert; M A Tainsky; N Bouck
Journal:  Science       Date:  1994-09-09       Impact factor: 47.728

View more
  21 in total

1.  Restoration of an absent G1 arrest and protection from apoptosis in embryonic stem cells after ionizing radiation.

Authors:  Yiling Hong; Peter J Stambrook
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-27       Impact factor: 11.205

Review 2.  Genetics of cerebral cavernous malformations.

Authors:  Nicholas W Plummer; Jon S Zawistowski; Douglas A Marchuk
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

3.  Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations.

Authors:  Nicholas W Plummer; Carol J Gallione; Sudha Srinivasan; Jon S Zawistowski; David N Louis; Douglas A Marchuk
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

Review 4.  Review of chromium (VI) apoptosis, cell-cycle-arrest, and carcinogenesis.

Authors:  A Chiu; X L Shi; W K P Lee; R Hill; T P Wakeman; A Katz; B Xu; N S Dalal; J D Robertson; C Chen; N Chiu; L Donehower
Journal:  J Environ Sci Health C Environ Carcinog Ecotoxicol Rev       Date:  2010-07       Impact factor: 3.781

Review 5.  Putting tumours in context.

Authors:  M J Bissell; D Radisky
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

6.  Combining Drosophila melanogaster somatic-mutation-recombination and electron-spin-resonance-spectroscopy data to interpret epidemiologic observations on chromium carcinogenicity.

Authors:  A J Katz; A Chiu; J Beaubier; X Shi
Journal:  Mol Cell Biochem       Date:  2001-06       Impact factor: 3.396

7.  Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer.

Authors:  Dae-Sung Yoon; Robert P Wersto; Weibo Zhou; Francis J Chrest; Elizabeth S Garrett; Teag Kyu Kwon; Edward Gabrielson
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

8.  Increase in mitochondrial biogenesis, oxidative stress, and glycolysis in murine lymphomas.

Authors:  Enrique Samper; Lucia Morgado; Juan C Estrada; Antonio Bernad; Alan Hubbard; Susana Cadenas; Simon Melov
Journal:  Free Radic Biol Med       Date:  2008-10-30       Impact factor: 7.376

9.  Mutagenesis in vivo in T cells of p21-deficient mice.

Authors:  Changshun Shao; Li Liang; Xin Zhao; Yanping Chen; Betty Zheng; Jianmin Chen; Minjie Luo; Jay A Tischfield
Journal:  Mutat Res       Date:  2009-09-08       Impact factor: 2.433

10.  Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

Authors:  Gabriel N Hortobagyi; David Chen; Martine Piccart; Hope S Rugo; Howard A Burris; Kathleen I Pritchard; Mario Campone; Shinzaburo Noguchi; Alejandra T Perez; Ines Deleu; Mikhail Shtivelband; Norikazu Masuda; Shaker Dakhil; Ian Anderson; Douglas M Robinson; Wei He; Abhishek Garg; E Robert McDonald; Hans Bitter; Alan Huang; Tetiana Taran; Thomas Bachelot; Fabienne Lebrun; David Lebwohl; José Baselga
Journal:  J Clin Oncol       Date:  2015-10-26       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.